# Rejuvenate Bio

Reversing age-related decline — proven in animals, advancing to humans

- Canonical URL: https://wefunder.com/rejuvenatebio
- Entity ID: wefunder:company:188422
- Last updated: 2026-06-08T03:04:18Z
- Generated at: 2026-06-08T03:19:51Z

## Quick facts
- Led by exited biotech entrepreneurs from Harvard, MIT, Duke, Princeton, and Caltech
- Co-founded by George Church, Harvard Medical School geneticist and TIME 100 scientist
- $130M+ in contracted development & commercial milestone payments across 6 animal health partnerships
- $5.1M in cumulative payments and in-kind services received from partners
- One-time injection gives years of treatment, with 2+ years of effect shown in dogs
- Radically cut manufacturing costs 10x to make doses accessible at $100/dose
- $250B+ market opportunity in the aging, metabolic & cardiac disease market
- $40M+ raised via nondilutive grants & investors: Digitalis, Kendall Capital Partners, & KdT Ventures

## Active fundraises
- wefunder:fundraise:149611: 4(a)(6) successful (USD)
- wefunder:fundraise:149610: 4(a)(6) open (USD)

## Story
Rejuvenate Bio develops groundbreaking one-shot gene therapies that target the root cause of aging and chronic disease. A single dose is designed to deliver lasting therapeutic benefit by reprogramming the body for youthful function.We built this company around a simple belief: aging takes far too much from the people and animals we love. Our mission is to restore health - rather than manage deterioration - so every person and animal can enjoy more healthy years together.Born out of George Church’s lab at Harvard Medical School, our team brings deep experience in genetics, synthetic biology, engineering, and gene therapy. The Rejuvenate Bio platform has shown disease reversal in dogs and life extension in mice, validating potential across species. That same platform has been backed by over $13M in non-dilutive awards from the U.S. Department of Defense and U.S. Special Operations Command to enhance human and canine performance – improving endurance, speed of recovery, and cognitive resilience in elite military operators and their working dogs.Backed by leading VC investors VCapital, Digitalis Ventures, Kendall Capital Partners, and KdT Ventures, Rejuvenate has raised $40M+ to reinvent aging as we know it. With more than $130M+ in contracted development and commercial milestone payments and projected double-digit-million royalty starting in 2028, Rejuvenate Bio is bringing longer, healthier lives within reach.Future projections are not guaranteed.Rejuvenate Bio has produced some of the strongest preclinical results in the field, with one gene therapy repairing cardiac damage and restoring metabolic health, and another extending lifespan in mice. A one-time injection gives years of treatment, with 2+ years of effect shown in dogs.Commercial partnerships with leading animal health companies are creating early revenue and $130M+ in contracted development and commercial milestone payments while we pursue clinical trials. Our high-yield manufacturing system produces doses for under $100, enabling accessible and affordable therapies for major cardiometabolic and aging-related diseases, never before seen in the modern healthcare system.The $130M+ in is contracted milestones that will be paid as our programs become commercial.Aging drives the chronic diseases that cut human and animal healthspans short. Today’s treatments are reactive, short-term, and aimed at symptoms, not the underlying genetic and cellular damage that links heart disease, kidney failure, obesity, and other age-related conditions.Six in ten Americans live with at least one chronic disease, and pets face similarly high burdens. Despite enormous need, there are no true disease-modifying treatments for many of these blockbuster conditions. The world needs a way to restore the body’s ability to repair itself.Rejuvenate Bio is creating a new class of medicine for a modern healthcare system. Our platform uses gene therapy to deliver DNA which allows the patient’s cells to create beneficial proteins, turning the body into a living factory that restores its own youthful function.Platform 1: Liver-directed gene therapyOur lead therapy, RJB-0402, uses an AAV8 viral vector to deliver the FGF21 gene to the liver. FGF21 is a naturally occurring protein that regulates metabolism, inflammation, and tissue repair. By restoring youthful levels of FGF21, this single-dose treatment has been shown to reverse cardiac damage and improve metabolic function in preclinical models.Platform 2: Epigenetic reprogrammingOur second technology resets how genes are expressed to reverse cellular aging itself. By selectively activating transcription factors, it restores youthful gene expression patterns without altering DNA. In mammals, this approach has been shown to double remaining lifespan, improve physical performance, and rejuvenate nerve and vision function in preclinical models.Manufacturing advantageFinally, Rejuvenate Bio’s proprietary high-yield manufacturing system cuts production costs to under $100 per dose, enabling affordable delivery of our therapies across animal and human health globally.Our dual-platform approach creates a foundation for rapid pipeline expansion across cardiovascular, metabolic, and neurodegenerative diseases, advancing a scalable strategy that treats the biology of aging itself.Our business model is simple. Develop one time, long acting therapies that can address multiple diseases, use animal health partnerships to help fund the science, generate milestone and royalty streams, and feed data and manufacturing directly into our human programs.Rejuvenate Bio’s development is faster and more efficient than traditional biotech. Success in animals directly accelerates human programs through shared studies, shared data, and shared manufacturing, creating earlier readouts and radical reductions in capital requirements.We operate with rigorous cash efficiency and are within view of cash flow positivity without traditional revenue.We have raised over $30M+ from leading investors including VCapital, Digitalis Ventures, Kendall Capital Partners, and KdT Ventures.Rejuvenate Bio has been recognized by Harvard Business School and MIT Technology Review for pioneering work in reversing aging and extending healthspan.In addition to private capital, we’ve been awarded over $13 million in non-dilutive SBIR/STTR funding from the U.S. Department of Defense and U.S. Special Operations Command, including programs in human performance optimization, neuroenhancement, and enhanced canine performance.Our investors and partners share a clear conviction: Rejuvenate Bio is positioned to redefine how chronic disease and aging are treated.Rejuvenate Bio was founded by Daniel Oliver and Dr. Noah Davidsohn, longtime collaborators who met at Caltech and later trained at Harvard and MIT under the guidance of world-renowned geneticist Dr. George Church. Their combined entrepreneurial experience and deep expertise in gene therapy and synthetic biology form a leadership team driven to change our healthspan.They are backed by accomplished scientists, industry veterans, and advisors from Harvard Medical School and leading global biotech firms, united by a shared commitment to restore health, extend vitality, and bring life-changing therapies to the people and animals who need them most.The global companion animal health market exceeds $23 billion and is projected to reach more than $40 billion by 2030, growing at ~9% annually. Demand for advanced veterinary care continues to rise as pet owners seek human-grade treatments for chronic disease.Our first commercial programs address mitral valve disease (the leading cardiac disease in dogs), obesity, and chronic kidney disease (one of the most prevalent serious conditions in cats), each representing multi-billion-dollar opportunities.In human health, the cardiometabolic and aging-related disease market exceeds $190 billion and is projected to surpass $300 billion by 2032.GLP-1 drugs started in diabetes and now also treat obesity and cardiovascular risk from the same core platform. We apply that same idea with gene therapy, using one platform to target multiple age-related diseases and reduce the time and capital needed to commercialize.Forward-looking statements are not guaranteed.Rejuvenate Bio has built an efficient, scalable model. Our partnerships with leading animal health groups, including Phibro and Protect Animal Health, represent multi-year development and commercialization agreements that provide both near-term inflows and long-term royalty potential. These partnerships also fund much of the R&D and manufacturing, reducing our burn and lowering the risk and cost of advancing each program.As veterinary therapies reach the market, royalty streams begin to grow, converting partner-funded development into long-term recurring income. Data and manufacturing efficiencies also accelerate our human programs, which means we don’t have to rebuild critical scientific infrastructure with each new platform.This dual-market strategy combines near-term partner-driven inflows with the long-term upside of human therapeutics, creating a capital-efficient path to aging and chronic disease breakthroughs.We have received $5.1M in cumulative payments and in-kind services received from partners. As programs advance, we unlock additional development milestones, including payments tied to progression decisions, GMP manufacturing runs, and eventual commercial launch.Once veterinary therapies reach the market, royalties become the primary driver of economic value. For our mitral valve disease program, we receive royalties on partner sales and additional commercial milestones based on cumulative sales growth. Across all agreements, we have $130M+ in contracted development and commercial milestone payments and projected double-digit-million royalties starting in 2028.Forward-looking statements are not guaranteed.We believe deeply in our fiduciary responsibility to investors, which is why we turned down an acceptance offer from Y Combinator when the economics were misaligned with our value - a standard of discipline we continue to uphold for our investors today.Forward-looking statements are not guaranteed.With only $3–4 million needed to reach cash flow positivity, we have a clear, capital-efficient path from commercial animal launches to first-in-human trials.The gene therapy sector has seen a series of high-value acquisitions, with multiple companies reaching multi-billion-dollar valuations. We’re poised to be at the center of the next great opportunity.Notable Comparables$8.7B acquisition of AveXis by Novartis (2018)$4.8B acquisition of Spark Therapeutics by Roche (2019)$3B acquisition of Audentes Therapeutics by Astellas (2019)$2B acquisition of AskBio by Bayer (2020)$5.2B acquisition of Akero Therapeutics by Novo Nordisk (2025)$3.5B acquisition of 89bio by Roche (2025)$1.2B acquisition of Boston Pharmaceuticals’ MASH asset by GSK (2025)These examples are simply illustrative. There is no guarantee we will experience a similar acquisition, if any. Forward-looking statements are not guaranteed.Rejuvenate Bio’s one-shot, one-time gene therapies restore youthful function and stop chronic disease at the source. Backed by scientists from Harvard, MIT, Duke, Princeton, and Caltech, we’re building the future of regenerative medicine.With this next round, we expect we can get to cash flow positivity, prove our success in animal and human clinical trials, and bring us all closer to the ultimate goal: reversing aging itself.Aging today is about managing decline. Join Rejuvenate Bio and invest in therapies that restore life.

## FAQ
1. **Does an investment (other than supporting the obvious good goals) only give the investor access to the "perks," and an ability in the future to purchase shares? Or does it give actual shares to the investor?**
   - Hey Eileen, as soon as we file our Form C with the SEC you will be asked to confirm your investment. Once you confirmed, you would fund the investment and receive shares in the company.
2. **Hi Daniel, Is $500,000.00 the maximum amount you are raising? If the round is oversubscribed would you be willing to increase the amount? Thank you, Glenn**
   - Hey Glenn, We are talking this over internally, but nothing to announce yet. Stay tuned! Dan
3. **I’m a veterinarian and clinic owner in Alberta, Canada. I 100% believe in these types of products for pets and truly think they will change the future of pet health. Before I dig in further, can Alberta/Canadian residents legally invest in this Wefunder round?**
   - I will reach out to wefunder and see what they say.

## Team
- Daniel Oliver (Co-Founder & CEO)
- Noah Davidsohn (Co-Founder & CSO)
- George Church (Co-Founder & Scientific Advisor)
- Dr. Fabian Kausche (Animal Health Advisor)
- Eric Hacherl (Manufacturing)
- Joseph Consiglio (Strategic Processes)
- Jeff Rudy (R&D Scale)
- Dr. Maritza McIntyre (Consultant (Advanced Therapies Partners))
- Richard Peluso (Consultant (RWP BioConsulting))
- Chien-Hung (Chris) Liu (Consultant)

## Q&A
- Q: Hey Glenn,We were just discussing this topic yesterday. No update yet, but expansion is something we are contemplating.
- Q: Hi Daniel, Is $500,000.00 the maximum amount you are raising? If the round is oversubscribed would you be willing to increase the amount? Thank you, Glenn
  - A: Hey Glenn, We are talking this over internally, but nothing to announce yet. Stay tuned! Dan
- Q: Does an investment (other than supporting the obvious good goals) only give the investor access to the "perks," and an ability in the future to purchase shares? Or does it give actual shares to the investor?
  - A: Hey Eileen, as soon as we file our Form C with the SEC you will be asked to confirm your investment. Once you confirmed, you would fund the investment and receive shares in the company.
- Q: Hello Daniel, Congrats on the funding success thus far. Great initiative and I love the possibilities. I have bunch of questions and I would like you to share your thoughts for the benefit of community too. - You have received $5.1 million in cumulative partner payments out of a potential $130 million. What are the exact technical or regulatory triggers required to unlock the next $10 million to $20 million in milestone payments? Are these triggers tied to conditional FDA approval in animals, or simply the completion of the current target dog trials? - The campaign indicates you need only $3 million to $4 million more to reach cash flow positive territory through animal launches and human trial progress. What is the precise timeline for reaching that cash flow positive state, and does that calculation assume your human trial s being fully funded by grants, or will human clinical trial costs eventually push you back into a burning cash state? - Achieving a $100 per dose manufacturing cost for an AAV vector would revolutionize the industry. Has this cost structure been achieved at true Current Good Manufacturing Practice clinical-grade scale, or is this an estimate based on smaller, research-grade lab yields? What specific proprietary modifications will allow you to achieve a 10x cost reduction compared to legacy gene therapy manufacturing? - You are currently managing six animal partnerships, scaling a proprietary manufacturing platform, doing military optimization work via DoD grants, and pushing a human cardiac asset toward an IND. With a lean team, how do you prevent operational diffusion? If a major animal partner demands an immediate, resource heavy pivot on a canine trial, does that risk delaying your 2028 human IND timeline? - Your leading human asset is for a specific, rare cardiac condition. How much of the safety and efficacy data generated from your canine Mitral Valve Disease trials is directly transferable to the FDA when filing the IND for this completely different human cardiac condition? Or does the human asset essentially require starting the regulatory data gathering from scratch? Feel free to drop me an email with any other supporting document. I am interested in this opportunity. I sent you a linkedin invite too.
- Q: I’m a veterinarian and clinic owner in Alberta, Canada. I 100% believe in these types of products for pets and truly think they will change the future of pet health. Before I dig in further, can Alberta/Canadian residents legally invest in this Wefunder round?
  - A: I will reach out to wefunder and see what they say.